Hania S Zayed1, Basma M Medhat2, Esraa M Seif1. 1. Rheumatology and Rehabilitation department, Faculty of Medicine, Cairo University, Kasr Al Ainy St., Cairo, 11562, Egypt. 2. Rheumatology and Rehabilitation department, Faculty of Medicine, Cairo University, Kasr Al Ainy St., Cairo, 11562, Egypt. basmamedhat@kasralainy.edu.eg.
Abstract
INTRODUCTION/ OBJECTIVES: Despite its importance, adherence to treatment has not been sufficiently studied in Behçet's disease (BD). The aim of this study was to evaluate medication adherence in BD using the Compliance Questionnaire of Rheumatology (CQR) and factors potentially affecting it. METHOD: This cross-sectional study included 67 consecutive BD patients including 57 (85%) males with a mean age of 35.1 ± 9.27 years and mean disease duration of 129 ± 91 months. The cumulative clinical manifestations, the Behçet's Disease Current Activity Form (BDCAF) score, and the Vasculitis Damage Index (VDI) were recorded. The CQR, Socioeconomic Status Questionnaire for Health Research in Egypt (SES), the Beliefs about Medication Questionnaire (BMQ), and the Short Form 36 (SF-36) quality of life assessment questionnaire were administered to the patients. Linear regression analysis was done to determine independent predictors of CQR. RESULTS: The mean BDCAF score was 3.27 ± 3.54 and the VDI was 3.36 ± 2.21. The mean CQR score was 69.2 ± 11.79. The CQR score varied significantly among different health sources (p = 0.02), with no relationship detected with other sociodemographic characteristics, nor with clinical characteristics or the SF-36. Among the investigated medications' complexities, severity of side effects showed significantly different CQR scores (p = 0.004), and a weak positive correlation between medications' numbers and the CQR was detected. Predictors for higher CQR scores included the necessity beliefs score of the BMQ (β = 1.1, p < 0.001); whereas, predictors for lower CQR scores were the harm and concern BMQ subscales ((β = - 1.5, p = 0.004) and (β = - 0.72, p = 0.032), respectively). CONCLUSIONS: Beliefs about medications were the only predictor for adherence in our cohort.
INTRODUCTION/ OBJECTIVES: Despite its importance, adherence to treatment has not been sufficiently studied in Behçet's disease (BD). The aim of this study was to evaluate medication adherence in BD using the Compliance Questionnaire of Rheumatology (CQR) and factors potentially affecting it. METHOD: This cross-sectional study included 67 consecutive BD patients including 57 (85%) males with a mean age of 35.1 ± 9.27 years and mean disease duration of 129 ± 91 months. The cumulative clinical manifestations, the Behçet's Disease Current Activity Form (BDCAF) score, and the Vasculitis Damage Index (VDI) were recorded. The CQR, Socioeconomic Status Questionnaire for Health Research in Egypt (SES), the Beliefs about Medication Questionnaire (BMQ), and the Short Form 36 (SF-36) quality of life assessment questionnaire were administered to the patients. Linear regression analysis was done to determine independent predictors of CQR. RESULTS: The mean BDCAF score was 3.27 ± 3.54 and the VDI was 3.36 ± 2.21. The mean CQR score was 69.2 ± 11.79. The CQR score varied significantly among different health sources (p = 0.02), with no relationship detected with other sociodemographic characteristics, nor with clinical characteristics or the SF-36. Among the investigated medications' complexities, severity of side effects showed significantly different CQR scores (p = 0.004), and a weak positive correlation between medications' numbers and the CQR was detected. Predictors for higher CQR scores included the necessity beliefs score of the BMQ (β = 1.1, p < 0.001); whereas, predictors for lower CQR scores were the harm and concern BMQ subscales ((β = - 1.5, p = 0.004) and (β = - 0.72, p = 0.032), respectively). CONCLUSIONS: Beliefs about medications were the only predictor for adherence in our cohort.
Entities:
Keywords:
Adherence; Behçet’s disease; Beliefs about medications; Compliance; Quality of life
Authors: Erik de Klerk; Désirée van der Heijde; Robert Landewé; Hille van der Tempel; Sjef van der Linden Journal: J Rheumatol Date: 2003-11 Impact factor: 4.666
Authors: Joyce A Cramer; Anuja Roy; Anita Burrell; Carol J Fairchild; Mahesh J Fuldeore; Daniel A Ollendorf; Peter K Wong Journal: Value Health Date: 2008 Jan-Feb Impact factor: 5.725
Authors: Bart J F van den Bemt; Frank H J van den Hoogen; Bart Benraad; Yechiel A Hekster; Piet L C M van Riel; Wim van Lankveld Journal: J Rheumatol Date: 2009-09-01 Impact factor: 4.666
Authors: Fatema T Elgengehy; Sherif M Gamal; Nesreen Sobhy; Ibrahem Siam; Ahmed M Soliman; Ghada W Elhady; Tamer A Gheita Journal: Adv Rheumatol Date: 2021-06-09